post event report - iqpc corporate › media › 1003768 › 71045.pdfindustry global ip exchange,...

POST EVENT REPORT IP Life Sciences Exchange 2015

A vivid cross-section of present IP challenges, interwoven with opportunities to discuss present needs with solution providers.

Deputy Head of IP Egis Pharmaceuticals

Great programme covering some of the most current topics in IP.

Assistant General Counsel Pfizer Inc.

Great event offering good networking opportunities due to its unique format - industry specific, selected delegates, one-to-one meetings, good size and great facilities.

Manager European Client Services

Murgitroyd

“

”44 (0) 207 368 9484 www.lifesciencesipexchange.com [email protected]

Post Event Report

CONTENTSWelcome Page 3

The event in numbers Page 4

Key attendance statistics Page 5

Delegate investment priorities Page 6

2015 IP Life Sciences session highlights Page 8

What did your peers really think? Page 9

With thanks to our partners Page 10

The 2016 speaker panel Page 11

How to get involved in a future Exchange meeting Page 12

44 (0) 207 368 9484 • www.lifesciencesipexchange.com • [email protected]

mailto:info%40thelegalexchangenetwork.com?subject=Enquiry%20from%20the%202015%20Life%20Science%20Exchange%20Post%20Event%20Report%20

WELCOMEIP Life Sciences Exchange (IPLS) 2015 arrived at a critical time for the industry, with landmark decisions and IP developments emerging daily from the pan- European framework. IPLS explored a range of crucial issues, including strategic planning to protect patents whilst engaging in the UPC, pathways to bringing generic drugs to the US market, integration of biosimilars and navigating new perimeters in patentable products influenced by key case law. In particular, IPLS focused on how such issues interacted with pharmaceuticals, biotechnology and chemicals companies. After all, these issues are critical components of an industry where Life Sciences companies are keen to protect innovation and retain their competitive advantage.

To address the challenges that come with protecting innovation and retaining competitive advantage, we brought together 50 CIPOs, Heads, Directors and VPs of IP and Patent for a packed two days of BrainWeave’s, group discussions, business meetings and informal networking opportunities.

Building on the success of our annual cross-industry Global IP Exchange, this forum of senior IP leaders was a great opportunity to share experiences and projects from across pharmaceuticals, biotechnology and chemicals.

This report will offer you an insight into the key themes and takeaways from the Exchange, as well an exclusive look at what is happening in the industry.



IP LIFE SCIENCES EXCHANGE IN STATS

DELEGATES

WHO ATTENDED IN 2016?

INDUSTRY

FUNCTIONAL RESPONSIBILITY

80% of delegates had

global responsibility

81% of delegates had a personal

annual budget of £500,000+

49% of delegates’ annual company

revenue was £1 billion +

Delegates came from

16 different countries

100% of attendees ranked the speakers as

Excellent, Very Good or Good

78% of delegates comprised VP, Director, Head, General Counsel

or CIPO job titles

Pharmaceuticals (Big)

Across All IP Disciplines 46.32%

Patents 12.1%

Patent, Licensing , Litigation 27.9%

Trademark, Brand Protection, Anti-Counterfeiting 9.47%

Licensing & Monetisation 4.21%

Pharmaceuticals (Medium)

Pharmaceuticals (Small)

Biotechnology Chemicals (Other)

26.32% 26.32% 23.68% 15.79% 7.89%



GLOBAL REACH


Global 71.05%Europe + USA 10.52%Emerging Markets 5.26%Europe 13.16%

REGIONAL RESPONSIBILITY

GEOGRAPHY

SWITZERLAND 15.79%

UK 13.16%

ISRAEL 10.53%

FRANCE 7.89%

THE NETHERLANDS 7.89%

USA 5.26%

GERMANY 5.26%

IRELAND 5.26%

SWEDEN 5.26%

SPAIN 5.26%

ITALY 5.26%

MALAYSIA 2.63%

POLAND 2.63%

FINLAND 2.63%

DENMARK 2.63%

BUDAPEST 2.63%


WHAT ARE THE DELEGATES PLANNING TO INVEST IN DURING 2016 - 2017?


IP Due Diligence 63.64%

Patent Litigation 57.58%

Licensing 57.58%

Competitive Research and Analysis 48.48%

Literature and Prior Art Search 45.45%

Patent Portfolio Management Tools 45.45%

Valuation Services 45.45%

IP Strategy & Innovation Consultants 42.42%

Legal Spend Management 39.39%

IP Investigations 36.36%

Patent Renewals Management 33.33%

Integrated IP Management Software 27.27%

Trademark Litigation 27.27%

IP Insurance Service 27.27%

Brand Monitoring 24.24%

Monetization Consultants 21.21%

Broker Services 18.18%

Translation Services 18.18%

Investment Category % of Delegates planning investment within 6 - 12 months of the Exchange


WHAT ARE DELEGATES’ TOP PROBLEMS IN 2016 – 2017?


Freedom To Operate in locations less well defined, like Russia, Australia, South Korea and Brazil

UPC: Learning and keeping up to date with impending rules, fees and strategies

Contract management and royalties’ payment management tools to deal with licensing terms

Cost efficient management of IP portfolio to take care

of annual payments for patents and applications IP Monetisation for patents not

in use: not right for internal commercialisation but could

be good for external licensing

Buy in to ensure agreement from

all parties on our objectives

Competitive analysis to track what others

are doing

Strategies to get into new markets, especially

emerging markets, in order to mitigate risk

IP litigation strategy in Europe, US & South America



2016 IP LIFE SCIENCES EXCHANGE SESSION HIGHLIGHTS

IP Enforcement Challenges in Emerging Markets Gabriel Kleiman, Assistant General Counsel, Pfizer Inc.Gabriel focused attendees’ attention on five points throughout his global IP enforcement presentation: • Have you considered the following when enforcing your patents in

emerging economies?• Will your patent be granted? If so, will it have sufficient scope to cover

your product?• Is your patent a reliable property right?• Will you be able to enforce your patent?• If you lose an enforcement action, have you considered whether there

would there be negative consequences?

Navigating New Perimeters in Patentable Products Influenced by Key Case Law: Stem CellsDr Ian Bryan, Senior IP Counsel, GE Healthcare Life SciencesIan focused on the potential of stem cells and ultimately what is patentable in stem cell innovations across Europe. In noting key case law such as Enlarged Board of Appeal (EBA): G2/06 Stem Cells/WARF, Ian ultimately concluded that:• Inventions based on adult stem cells are patentable• hESC based inventions based on parthenogenesis after 5 June 2003* are

patentable• hESC based inventions on Single Cell Blastomere Biopsy after 10 January

2008** are patentable• Induced pluripotent stem cell based inventions are patentable• hESC inventions exclusively necessitating human embryo destruction are

NOT patentable

Mapping the Pathway to Successfully Conducting Multijurisdictional LitigationDr.Toni Santamaria, Head of IP, Europe, AccordToni’s session was of strategic interest to those delegates involved in multi-jurisdictional litigation. In particular, Toni suggested successful litigation rested on your team, commercial goals and strategy and had to consider the following:• Plan strategy but be ready to change the plans• Align IP with business interests• Consider all the costs and risks involved• Appoint the best possible team

ENFORCEMENT AND PROTECTION

CASE LAW DEVELOPMENTS

LITIGATION


It was great to meet with colleagues in the field and get everyone's perspective on important impending changes and developments in the legislative arena as well from the courts.

Sr VP IP ProQR Therapeutics

Really was a good forum to exchange common challenges and possible solutions.

VP IP Neurology/Neurotoxin

Ipsen Pharma

Very intense. Interesting topics and interesting people-providers.

Chief IP Officer AB-Bioticsm

Very interesting and relevant. I got the impression that particularly on the first day many issues were addressed with which many IP counsels have to deal at present.

IP Counsel Vifor Pharma

A good opportunity to meet like-minded professionals and keep up to date with the field.

IP Manager Enigma Diagnostics

“

“

“

“

“

“

”

”

”

”

”

”

Very interesting and professional. The mix between talks, round tables, and personal meetings was very good.

Intellectual Property Director, Life Sciences,

B.G. Negev Technologies and Applications Ltd.

MANY THANKS TO OUR 2015 SPONSORS AND MEDIA PARTNERS

Sponsors

Media Partners

HGF HGF



MANY THANKS TO OUR FANTASTIC 2015 SPEAKER PANEL

IP Life Sciences Exchange Speakers Included:

Roya Ghafele Director, OxFirst Ltd. and Fellow St Cross College, Oxford

Seth FidelLead IP Counsel Merrimack Pharma

Alexander RamsayVice ChairmanUPC

Gabe Kleiman Assistant General Counsel Pfizer

Toni Santamaria Head of Intellectual Property, Europe Accord Healthcare

Henrik MathiassenHead of Patent DepartmentZealand Pharma

Ian BryanIP CounselGE Health Care

Bernd HutterHead of IP MorphoSys AG

Jürgen DresselHead Global Patent Litigation StrategyNovartis Pharma

Anna Coleman Senior Counsel Teva Pharmaceuticals

Harry KraftSenior Patent AttorneyAblynx




JOIN US IN 2016!

The 2nd IP Life Sciences Exchange will bring together 80 senior IP decision makers plus hand-selected solution providers for two days of interactive networking and senior level benchmarking. This popular invitation only meeting is open to Chief IP Officers, General Counsel, VPs, Directors and Heads of IP and Patents who want to drive their IP strategy to success.

• Discover what strategies and solutions innovative companies are adopting

• Develop new business partnerships through a range of interactive networking opportunities

• Participate in intimate working groups with senior peers to help overcome common challenges and develop new strategies

To ensure that you are in the best position to implement proven solutions to your daily challenges, IPLS continues to be delivered by the highest ranked experts within the Life Sciences community.

The IP Life Sciences Exchange is the ‘must-attend’ event in the Life Sciences calendar.

15 - 16 November 2016, Germany

Request your invitation




LEGAL EVENT PORTFOLIO

Global IP Exchange March, Germany

Global IP Exchange US December, San Diego

Corporate Counsel & Compliance Exchange | April, London UK

Corporate Counsel Exchange October, Germany

IP Life Sciences Exchange November, Germany

Corporate Counsel Exchange Financial Services December, London, UK

Pat-Tech Exchange June, Dublin, Ireland

Information Governance Exchange June, Atlanta, Georgia, USA


http://www.globalipexchange.co.uk/

mailto:info%40thelegalexchangenetwork.com?subject=I%20would%20like%20to%20find%20out%20more%20about%20the%20Global%20IP%20Exchange%20US

http://www.corporatecounselexchange.co.uk/

http://www.corporatecounselexchange.co.uk/

http://www.lifesciencesipexchange.com/

http://www.corporatecounselexchangefinancialservices.com/

http://globalpatentstrategyexchange.com/

http://informationgovernanceexchange.com/

post event report - iqpc corporate › media › 1003768 › 71045.pdfindustry global ip exchange,...

Documents